Source: Pharmabiz

Vaxxel: Vaxxel buys Transgene's DuckCeltT17 cell line to develop industrialscale vaccines against respiratory viruses

Vaxxel SAS, a French start─up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene's proprietary DuckCelt─T17 cell line. The terms of the agreement

Read full article »

Vaxxel's Competitors | Vaxxel's News | Vaxxel's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

President & CEO

Denis Cavert

CEO Approval Rating

90/100

Vaxxel is a France-based biotechnology company that develops and commercializes live-attenuated vaccine candidates to treat bronchiolitis and pneumonia.